Antibody | Cases (n = 200) | Controls (n = 200) | Trend Testb | |||
---|---|---|---|---|---|---|
% | % | OR (95 % CIc) | P d | OR (95 % CIc) | P d | |
HPV 16 | ||||||
E6 | 0.5 | 1.4 | 0.39 (0.04–3.79) | 0.462 | 1.17 (0.97–1.43) | 0.097 |
E7 | 9.3 | 7.8 | 1.22 (0.60–2.47) | 0.603 | 1.06 (0.97–1.15) | 0.182 |
L1 | 4.4 | 3.7 | 1.17 (0.43–3.21) | 0.746 | 1.04 (0.95–1.15) | 0.374 |
HPV 18 | ||||||
E6 | 1.6 | 1.4 | 1.18 (0.23–5.93) | 0.877 | 1.02 (0.93–1.13) | 0.632 |
E7 | 1.6 | 1.4 | 1.18 (0.23–5.93) | 0.877 | 1.06 (0.93–1.21) | 0.404 |
L1 | 0.5 | 1.8 | 0.29 (0.03–2.66) | 0.229 | 1.00 (0.91–1.11) | 0.948 |
Other high-risk HPV | ||||||
31 L1 | 6.6 | 8.8 | 0.72 (0.34–1.53) | 0.402 | 1.00 (0.92–1.09) | 0.988 |
33 L1 | 0.5 | 0.5 | 1.23 (0.08–20.03) | 0.887 | 1.03 (0.93–1.15) | 0.537 |
52 L1 | 34.4 | 33.6 | 1.04 (0.68–1.57) | 0.883 | 1.00 (0.90–1.11) | 0.989 |
58 L1 | 13.7 | 12.0 | 1.17 (0.65–2.10) | 0.611 | 1.03 (0.94–1.12) | 0.543 |
Low-risk HPV | ||||||
6 L1 | 45.4 | 38.2 | 1.34 (0.89–2.00) | 0.167 | 1.03 (0.95–1.11) | 0.503 |
11 L1 | 20.2 | 13.8 | 1.58 (0.93–2.68) | 0.097 | 1.05 (0.97–1.14) | 0.229 |